{"disease":{"id":"depressive","name":"depressive"},"drugs":{"marketed":[{"drug_id":"rexulti","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rexulti","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6, D(4) dopamine receptor","drug_class":"","quality_score":24,"revenue":"1400","mechanism":null},{"drug_id":"brexpiprazole","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rexulti","generic_name":"BREXPIPRAZOLE","company_name":"Otsuka","drug_phase":"marketed","molecular_target":"D(2) dopamine receptor","drug_class":"Atypical Antipsychotic [EPC]","quality_score":60,"revenue":"1400","mechanism":""},{"drug_id":"desvenlafaxine","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pristiq","generic_name":"desvenlafaxine","company_name":"Alembic Pharms Ltd","drug_phase":"marketed","molecular_target":"Sodium-dependent serotonin transporter","drug_class":"Serotonin and Norepinephrine Reuptake Inhibitor","quality_score":82,"revenue":"1041.0","mechanism":"Pristiq works by blocking the reabsorption of serotonin and norepinephrine in the brain, allowing more of these neurotransmitters to be available for use."},{"drug_id":"pristiq","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pristiq","generic_name":"Desvenlafaxine Succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serotonin and norepinephrine reuptake","drug_class":"Serotonin-norepinephrine reuptake inhibitor (SNRI)","quality_score":75,"revenue":"1041.0","mechanism":"Potentiates serotonin and norepinephrine in CNS through reuptake inhibition."},{"drug_id":"fluoxetine","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prozac","generic_name":"fluoxetine","company_name":"Eli Lilly and Company","drug_phase":"marketed","molecular_target":"Serotonin reuptake transporter","drug_class":"Selective Serotonin Reuptake Inhibitor (SSRI)","quality_score":81,"revenue":"1000.0","mechanism":"Fluoxetine inhibits CNS neuronal uptake of serotonin, though exact mechanism unknown."},{"drug_id":"fluoxetine","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prozac","generic_name":"fluoxetine","company_name":"Eli Lilly and Company","drug_phase":"marketed","molecular_target":"Serotonin reuptake transporter","drug_class":"Selective Serotonin Reuptake Inhibitor (SSRI)","quality_score":81,"revenue":"1000.0","mechanism":"Fluoxetine inhibits CNS neuronal uptake of serotonin, though exact mechanism unknown."},{"drug_id":"vortioxetine","indication_name":"Major Depressive Disorder (MDD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trintellix","generic_name":"vortioxetine","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor","drug_class":"Serotonin modulator and stimulator (SMS); SSRI-like agent","quality_score":78,"revenue":"800","mechanism":"Vortioxetine enhances serotonergic activity through serotonin reuptake inhibition with additional 5-HT3 antagonism and 5-HT1A agonism."},{"drug_id":"esketamine","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Spravato","generic_name":"ESKETAMINE","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"","drug_class":"esketamine","quality_score":62,"revenue":"800","mechanism":"Spravato works by blocking the action of glutamate, a neurotransmitter involved in mood regulation."},{"drug_id":"spravato","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Spravato","company_name":"Yale University","drug_phase":"marketed","molecular_target":"Glutamate NMDA receptor","drug_class":"","quality_score":27,"revenue":"800","mechanism":null},{"drug_id":"vortioxetine","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trintellix","generic_name":"vortioxetine","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor","drug_class":"Serotonin modulator and stimulator (SMS); SSRI-like agent","quality_score":78,"revenue":"800","mechanism":"Vortioxetine enhances serotonergic activity through serotonin reuptake inhibition with additional 5-HT3 antagonism and 5-HT1A agonism."},{"drug_id":"sertraline","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zoloft","generic_name":"sertraline","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Melanocortin receptor 5, 5-hydroxytryptamine receptor 2A","drug_class":"SSRI (Selective serotonin reuptake inhibitor)","quality_score":71,"revenue":"350","mechanism":"Selective serotonin reuptake inhibitor (SSRI) that blocks the serotonin transporter, increasing synaptic serotonin to improve mood and reduce anxiety."},{"drug_id":"olanzapine","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyprexa","generic_name":"olanzapine","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":"300","mechanism":null},{"drug_id":"dosulepin","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dothiepin","generic_name":"Dosulepin","company_name":"All India Institute of Medical Sciences, Bhubaneswar","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Tricyclic Antidepressants","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"levomilnacipran","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fetzima","generic_name":"LEVOMILNACIPRAN","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Sodium-dependent serotonin transporter","drug_class":"Serotonin and Norepinephrine Reuptake Inhibitor","quality_score":64,"revenue":null,"mechanism":"Fetzima works by blocking the reabsorption of serotonin and norepinephrine in the brain, allowing more of these neurotransmitters to be available for communication between brain cells."},{"drug_id":"vilazodone","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Viibryd","generic_name":"vilazodone","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 4, 5-hydroxytryptamine receptor 7","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"selegiline","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Selegiline Hydrochloride","generic_name":"SELEGILINE","company_name":"Somerset","drug_phase":"marketed","molecular_target":"Amine oxidase [flavin-containing] B","drug_class":"Monoamine Oxidase Inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"chlordiazepoxide","indication_name":"Mixed anxiety and depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chlordiazepoxide Hydrochloride","generic_name":"CHLORDIAZEPOXIDE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Benzodiazepine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"duloxetine","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cymbalta","generic_name":"duloxetine","company_name":"Eli Lilly and Company","drug_phase":"marketed","molecular_target":"Serotonin and norepinephrine reuptake","drug_class":"Serotonin and norepinephrine reuptake inhibitor (SNRI)","quality_score":68,"revenue":null,"mechanism":"Potentiates serotonergic and noradrenergic activity in the CNS through unknown exact mechanisms."},{"drug_id":"desipramine","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norpramin","generic_name":"DESIPRAMINE","company_name":"Validus Pharms","drug_phase":"marketed","molecular_target":"Sodium-dependent dopamine transporter","drug_class":"Tricyclic Antidepressant","quality_score":54,"revenue":null,"mechanism":""},{"drug_id":"agomelatine","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thymanax","generic_name":"AGOMELATINE","company_name":"Les Laboratoires Servier","drug_phase":"marketed","molecular_target":"Melatonin receptor type 1A","drug_class":"agomelatine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"amoxapine","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amoxan","generic_name":"AMOXAPINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Tricyclic Antidepressant [EPC]","quality_score":54,"revenue":null,"mechanism":""},{"drug_id":"amineptine","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amineptin","generic_name":"AMINEPTINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"amineptine","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"gepirone","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"GEPIRONE","company_name":"","drug_phase":"marketed","molecular_target":"5HT1A receptors","drug_class":"gepirone","quality_score":53,"revenue":null,"mechanism":"EXXUA's antidepressant effect may stem from modulating serotonergic activity via selective agonist activity at 5HT1A receptors."},{"drug_id":"bupropion-sr-150mg-bid","indication_name":"Treatment of Major Depressive Disorder (MDD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bupropion SR 150mg bid","company_name":"Massachusetts General Hospital","drug_phase":"marketed","molecular_target":"Dopamine transporter (DAT), Norepinephrine transporter (NET)","drug_class":"Atypical antidepressant, Norepinephrine-dopamine reuptake inhibitor (NDRI)","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"caroxazone","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Timostenil","generic_name":"CAROXAZONE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"caroxazone","quality_score":null,"revenue":null,"mechanism":"Timostenil is thought to work by modulating neurotransmitter activity in the brain."},{"drug_id":"paroxetine","indication_name":"Major Depressive Disorder (MDD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Paroxetine","generic_name":"paroxetine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Serotonin (5-HT) reuptake transporter","drug_class":"Selective Serotonin Reuptake Inhibitor (SSRI)","quality_score":73,"revenue":null,"mechanism":"Inhibits neuronal reuptake of serotonin in the central nervous system, presumed mechanism for treating psychiatric disorders."},{"drug_id":"bat","indication_name":"Treatment of major depressive disorder in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"placebp","indication_name":"Major Depressive Disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Placebp","generic_name":"placebp","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"None","drug_class":"Placebo","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"bupropion-immediate-release-ir","indication_name":"Major Depressive Disorder (MDD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bupropion immediate release (IR)","generic_name":"bupropion-immediate-release-ir","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Dopamine transporter, Norepinephrine transporter","drug_class":"Norepinephrine-dopamine reuptake inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"nefazodone","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Serzone","generic_name":"NEFAZODONE","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Sodium-dependent serotonin transporter","drug_class":"Serotonin Reuptake Inhibitor","quality_score":54,"revenue":null,"mechanism":""},{"drug_id":"mianserin","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(+/-)-Mianserin","generic_name":"MIANSERIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"mianserin","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"escitalopram","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lexapro","generic_name":"escitalopram","company_name":"Generic (originally Lundbeck/Forest)","drug_phase":"marketed","molecular_target":"Serotonin (5-HT) reuptake transporter","drug_class":"Selective Serotonin Reuptake Inhibitor (SSRI)","quality_score":61,"revenue":null,"mechanism":"Inhibits CNS neuronal reuptake of serotonin (5-HT), potentiating serotonergic activity."},{"drug_id":"opipramol","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opramidol","generic_name":"OPIPRAMOL","company_name":"","drug_phase":"phase_3","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"opipramol","quality_score":null,"revenue":null,"mechanism":"Opipramol works by binding to the sigma non-opioid intracellular receptor 1, which helps to regulate mood and emotional responses."},{"drug_id":"lofepramine","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lopramine","generic_name":"LOFEPRAMINE","company_name":"","drug_phase":"marketed","molecular_target":"Sodium-dependent noradrenaline transporter","drug_class":"Tricyclic Antidepressants","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"mebanazine","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Actomol","generic_name":"MEBANAZINE","company_name":"","drug_phase":"marketed","molecular_target":"Amine oxidase [flavin-containing] A","drug_class":"Monoamine Oxidase Inhibitors","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"butriptyline","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Butriptylene","generic_name":"BUTRIPTYLINE","company_name":"","drug_phase":"phase_2","molecular_target":"Sodium-dependent serotonin transporter","drug_class":"butriptyline","quality_score":null,"revenue":null,"mechanism":"Butriptyline works by blocking the reuptake of serotonin, a neurotransmitter involved in mood regulation, allowing more serotonin to be available in the brain."},{"drug_id":"demexiptiline","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deparon","generic_name":"DEMEXIPTILINE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Deparon is thought to work by influencing neurotransmitter levels in the brain."},{"drug_id":"iproclozide","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Iproclozid","generic_name":"IPROCLOZIDE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"Monoamine Oxidase Inhibitors","quality_score":null,"revenue":null,"mechanism":"Iproclozide works by blocking the enzyme that breaks down certain neurotransmitters in the brain, allowing their levels to increase and improve mood."},{"drug_id":"ethyl-loflazepate","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Meilax","generic_name":"ETHYL LOFLAZEPATE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"ethyl loflazepate","quality_score":null,"revenue":null,"mechanism":"Meilax works by enhancing the activity of a neurotransmitter called gamma-aminobutyric acid (GABA), which helps to calm the brain and reduce anxiety."},{"drug_id":"venlafaxine","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Effexor","generic_name":"venlafaxine","company_name":"Generic (originally Wyeth/Pfizer)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C","drug_class":"SNRI (Serotonin-norepinephrine reuptake inhibitor)","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"sertralin","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sertralin","company_name":"Poznan University of Medical Sciences","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Melanocortin receptor 5, 5-hydroxytryptamine receptor 2A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"prozac","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prozac","company_name":"RenJi Hospital","drug_phase":"marketed","molecular_target":"Equilibrative nucleoside transporter 4, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"prozac","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prozac","company_name":"RenJi Hospital","drug_phase":"marketed","molecular_target":"Equilibrative nucleoside transporter 4, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"bupropion","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wellbutrin","generic_name":"bupropion","company_name":"GSK (GlaxoSmithKline)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor","drug_class":"NDRI (Norepinephrine-dopamine reuptake inhibitor)","quality_score":55,"revenue":null,"mechanism":"Norepinephrine-dopamine reuptake inhibitor (NDRI) that treats depression and aids smoking cessation without serotonergic side effects."},{"drug_id":"bupropion","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wellbutrin","generic_name":"bupropion","company_name":"GSK (GlaxoSmithKline)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor","drug_class":"NDRI (Norepinephrine-dopamine reuptake inhibitor)","quality_score":55,"revenue":null,"mechanism":"Norepinephrine-dopamine reuptake inhibitor (NDRI) that treats depression and aids smoking cessation without serotonergic side effects."},{"drug_id":"parnate","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Parnate","company_name":"Par Pharmaceutical, Inc.","drug_phase":"marketed","molecular_target":"7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Cytochrome P450 2B6, Lysine-specific histone demethylase 1B","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"protriptyline","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Triptil","generic_name":"PROTRIPTYLINE","company_name":"","drug_phase":"marketed","molecular_target":"Adenosine receptor A3","drug_class":"Tricyclic Antidepressant","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"maprotiline","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MAPROTILINE","company_name":"","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor","drug_class":"maprotiline","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"maprotiline","indication_name":"Mixed anxiety and depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MAPROTILINE","company_name":"","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor","drug_class":"maprotiline","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"nortriptyline","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aventyl","generic_name":"NORTRIPTYLINE","company_name":"","drug_phase":"marketed","molecular_target":"Sodium-dependent noradrenaline transporter","drug_class":"Tricyclic Antidepressant","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"imipramine","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tofranil","generic_name":"IMIPRAMINE","company_name":"","drug_phase":"marketed","molecular_target":"Sodium-dependent serotonin transporter","drug_class":"Tricyclic Antidepressant","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"perphenazine","indication_name":"Mixed anxiety and depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trilafon","generic_name":"PERPHENAZINE","company_name":"","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Phenothiazine [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"nardil","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nardil","generic_name":"Phenelzine Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Amine oxidase [flavin-containing] B","drug_class":"Monoamine Oxidase Inhibitor","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"effexor-xr","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Effexor","generic_name":"Venlafaxine Hydrochloride","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serotonin and norepinephrine reuptake transporters","drug_class":"Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)","quality_score":70,"revenue":null,"mechanism":"Potentiates serotonin and norepinephrine in CNS through reuptake inhibition."},{"drug_id":"citalopram","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celexa","generic_name":"CITALOPRAM","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Sodium-dependent serotonin transporter","drug_class":"Serotonin Reuptake Inhibitor","quality_score":80,"revenue":null,"mechanism":"Celexa works by blocking the reabsorption of serotonin in the brain, allowing more of this neurotransmitter to be available for communication between nerve cells."},{"drug_id":"citalopram","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celexa","generic_name":"CITALOPRAM","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Sodium-dependent serotonin transporter","drug_class":"Serotonin Reuptake Inhibitor","quality_score":80,"revenue":null,"mechanism":"Celexa works by blocking the reabsorption of serotonin in the brain, allowing more of this neurotransmitter to be available for communication between nerve cells."},{"drug_id":"doxepin","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zonalon","generic_name":"DOXEPIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Tricyclic Antidepressant","quality_score":80,"revenue":null,"mechanism":"Zonalon works by blocking histamine H1 receptors in the brain, which helps to reduce anxiety and itching, and improve mood."},{"drug_id":"nortriptyline-hydrochloride","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aventyl","generic_name":"NORTRIPTYLINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"Sodium-dependent noradrenaline transporter","drug_class":"Tricyclic Antidepressant","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"phenelzine","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nardil","generic_name":"PHENELZINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Amine oxidase [flavin-containing] B","drug_class":"Monoamine Oxidase Inhibitor","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"trimipramine","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Surmontil","generic_name":"TRIMIPRAMINE","company_name":"Teva Womens","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Tricyclic Antidepressant","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tranylcypromine","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Parnate","generic_name":"TRANYLCYPROMINE","company_name":"Advanz","drug_phase":"marketed","molecular_target":"Amine oxidase [flavin-containing] B","drug_class":"Monoamine Oxidase Inhibitor","quality_score":75,"revenue":null,"mechanism":"Parnate works by blocking an enzyme that breaks down certain neurotransmitters, allowing them to stay in the brain longer."},{"drug_id":"trazodone","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Desyrel","generic_name":"trazodone","company_name":"Generic (originally Angelini/Pragmaten)","drug_phase":"marketed","molecular_target":"HLA class I histocompatibility antigen, A-3 alpha chain, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A","drug_class":"SARI (Serotonin antagonist and reuptake inhibitor)","quality_score":57,"revenue":null,"mechanism":"Serotonin antagonist and reuptake inhibitor (SARI) that blocks 5-HT2A receptors and H1 receptors, used primarily as a sedative-hypnotic at low doses."},{"drug_id":"dextromethorphan","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Delsym","generic_name":"dextromethorphan","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 46, Solute carrier family 22 member 1, Cytochrome P450 2D6","drug_class":"Antitussive (non-opioid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"amitriptyline","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Endep","generic_name":"AMITRIPTYLINE","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Tricyclic Antidepressant","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"amitriptyline","indication_name":"Mixed anxiety and depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Endep","generic_name":"AMITRIPTYLINE","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Tricyclic Antidepressant","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"mirtazapine","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Remeron","generic_name":"mirtazapine","company_name":"Generic (originally Organon/MSD)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C","drug_class":"NaSSA (Noradrenergic and specific serotonergic antidepressant)","quality_score":10,"revenue":null,"mechanism":"Noradrenergic and specific serotonergic antidepressant (NaSSA) that blocks alpha-2 adrenergic, 5-HT2, 5-HT3, and H1 receptors."},{"drug_id":"effexor","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Effexor","company_name":"Wyeth is now a wholly owned subsidiary of Pfizer","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cital","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cital","company_name":"Ain Shams University","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cital","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cital","company_name":"Ain Shams University","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"amitryptiline","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amitryptiline","company_name":"Mahatma Gandhi Institute of Medical Sciences","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 6, D(1B) dopamine receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"amitryptiline","indication_name":"Mixed anxiety and depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amitryptiline","company_name":"Mahatma Gandhi Institute of Medical Sciences","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 6, D(1B) dopamine receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"wellbutrin","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Wellbutrin","company_name":"Mclean Hospital","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"wellbutrin","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Wellbutrin","company_name":"Mclean Hospital","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xanax","indication_name":"Mixed anxiety and depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xanax","company_name":"National Taiwan University Hospital","drug_phase":"marketed","molecular_target":"Bromodomain-containing protein 4, Platelet-activating factor receptor, Cytochrome P450 3A4","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zelapar","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zelapar","company_name":"Baylor College of Medicine","drug_phase":"marketed","molecular_target":"Alpha-synuclein, Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zyprexa","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zyprexa","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"elontril","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Elontril","company_name":"Boehringer Ingelheim","drug_phase":"phase_3","molecular_target":"Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"elontril","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Elontril","company_name":"Boehringer Ingelheim","drug_phase":"phase_3","molecular_target":"Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"gepirone","indication_name":"Major Depressive Disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"GEPIRONE","company_name":"","drug_phase":"marketed","molecular_target":"5HT1A receptors","drug_class":"gepirone","quality_score":53,"revenue":null,"mechanism":"EXXUA's antidepressant effect may stem from modulating serotonergic activity via selective agonist activity at 5HT1A receptors."},{"drug_id":"alprazolam","indication_name":"Mixed anxiety and depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xanax","generic_name":"alprazolam","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Bromodomain-containing protein 4, Platelet-activating factor receptor, Cytochrome P450 3A4","drug_class":"Benzodiazepine (triazolobenzodiazepine)","quality_score":0,"revenue":null,"mechanism":"Short-acting, high-potency benzodiazepine that enhances GABA-A receptor activity, providing rapid anxiolytic relief."},{"drug_id":"chembl-chembl894","indication_name":"Treatment of Major Depressive Disorder (MDD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BUPROPION","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"citalopram-hydrobromide","indication_name":"Major Depressive Disorder (MDD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CITALOPRAM HYDROBROMIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"desvenlafaxine-succinate","indication_name":"Major Depressive Disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DESVENLAFAXINE SUCCINATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl809","indication_name":"Major Depressive Disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SERTRALINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1118","indication_name":"Major Depressive Disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DESVENLAFAXINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"ly4064809","indication_name":"Treatment of major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ly4064809","generic_name":"ly4064809","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":32,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"moclobemide","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Auromid","generic_name":"MOCLOBEMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Amine oxidase [flavin-containing] A","drug_class":"Monoamine Oxidase Inhibitors","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"toloxatone","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Humoryl","generic_name":"TOLOXATONE","company_name":"","drug_phase":"marketed","molecular_target":"Amine oxidase [flavin-containing] A","drug_class":"Monoamine Oxidase Inhibitors","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"reboxetine","indication_name":"Major depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Edronax","generic_name":"REBOXETINE","company_name":"","drug_phase":"marketed","molecular_target":"Sodium-dependent noradrenaline transporter","drug_class":"reboxetine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"setiptiline","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tecipul","generic_name":"SETIPTILINE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":"Tecipul is thought to work by modulating neurotransmitter activity in the brain."},{"drug_id":"iproniazid","indication_name":"Depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Iprazid","generic_name":"IPRONIAZID","company_name":"","drug_phase":"phase_2","molecular_target":"Amine oxidase [flavin-containing] A","drug_class":"Monoamine Oxidase Inhibitors","quality_score":null,"revenue":null,"mechanism":"Iproniazid works by blocking the enzyme that breaks down certain neurotransmitters, allowing their levels to increase in the brain."}],"pipeline":[],"offLabel":[],"totalMarketed":91,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03109002","title":"An Epidemiology Study of Treatment Resistant Depression in the United States (US)","phase":"","overall_status":"COMPLETED","enrollment_count":200000,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT05932407","title":"A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression","phase":"","overall_status":"COMPLETED","enrollment_count":147777,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT07453420","title":"Profiling Vulnerability and Resilience for Mental Illness Following Viral Infections: Translating Epidemiology to Deep-phenotyping.","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Shalvata Mental Health Center","has_results":false},{"nct_id":"NCT05095662","title":"Establish a Specific Cohort Database for Depressive Disorders","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80000,"lead_sponsor_name":"Shanghai Mental Health Center","has_results":false},{"nct_id":"NCT05952713","title":"Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder","phase":"","overall_status":"COMPLETED","enrollment_count":73336,"lead_sponsor_name":"Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital","has_results":false},{"nct_id":"NCT04239521","title":"The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":51955,"lead_sponsor_name":"Momentum Data","has_results":false},{"nct_id":"NCT06070766","title":"RIVER At Home Ketamine Protocols","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"RIVER Foundation","has_results":false},{"nct_id":"NCT06641726","title":"Creating a Global Research Database That Connects Genetic Information and Long-term Health Data to Improve Personalized Treatment for People With Serious Mental Illness","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Akrivia Health","has_results":false},{"nct_id":"NCT02425345","title":"Women's Health Initiative Strong and Healthy Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":49331,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT04953338","title":"Mental Health Associations With Vitiligo","phase":"","overall_status":"COMPLETED","enrollment_count":36104,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT05816018","title":"Improving Health Care in Major Depressive Disorder","phase":"","overall_status":"UNKNOWN","enrollment_count":30900,"lead_sponsor_name":"Ospedale San Raffaele","has_results":false},{"nct_id":"NCT07015944","title":"Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in Pakistan","phase":"NA","overall_status":"RECRUITING","enrollment_count":26376,"lead_sponsor_name":"Pakistan Institute of Living and Learning","has_results":false},{"nct_id":"NCT07281729","title":"Investigation on Risk Factors for Suicide Among Chinese Patients With Mood Disorders","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":25000,"lead_sponsor_name":"Shanghai Mental Health Center","has_results":false},{"nct_id":"NCT05206734","title":"Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health","phase":"","overall_status":"COMPLETED","enrollment_count":19469,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT03699488","title":"Messaging Therapy for Depression and Anxiety: A Longitudinal Effectiveness Study","phase":"","overall_status":"COMPLETED","enrollment_count":12980,"lead_sponsor_name":"Talkspace","has_results":false},{"nct_id":"NCT03716869","title":"Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder","phase":"NA","overall_status":"COMPLETED","enrollment_count":12909,"lead_sponsor_name":"Milton S. Hershey Medical Center","has_results":true},{"nct_id":"NCT06155201","title":"Development and Application of Intelligent Diagnosis and Treatment Norms for Children and Adolescents With Mental Disorders","phase":"NA","overall_status":"UNKNOWN","enrollment_count":12000,"lead_sponsor_name":"Chen Li","has_results":false},{"nct_id":"NCT04444713","title":"Do Network Centrality Predict Overall Depression Symptom Reduction With Lifting of Social Distancing Protocols?","phase":"","overall_status":"UNKNOWN","enrollment_count":10084,"lead_sponsor_name":"Modum Bad","has_results":false},{"nct_id":"NCT05480150","title":"Chinese Longitudinal and Systematic Study of Bioplar Disorder","phase":"NA","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT07305701","title":"Cohort Study on Medical Students' Mental Health","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Centre Hospitalier Régional d'Orléans","has_results":false},{"nct_id":"NCT05356078","title":"Association Between Prescription of Antidepressants and Delirium in the Elderly : Analysis From the World Health Organization Global Database","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT05267873","title":"Combining Data Sources to Identify Effect Moderation for Personalized Mental Health","phase":"","overall_status":"COMPLETED","enrollment_count":9586,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT04282915","title":"Reducing Stigma Among Healthcare Providers (RESHAPE-cRCT)","phase":"NA","overall_status":"COMPLETED","enrollment_count":8705,"lead_sponsor_name":"George Washington University","has_results":false},{"nct_id":"NCT02691520","title":"Epidemiology of Treatment Resistant Depression in Taiwan","phase":"","overall_status":"COMPLETED","enrollment_count":8356,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT06856668","title":"A Megastudy of Single-Session Interventions for Depression","phase":"NA","overall_status":"COMPLETED","enrollment_count":7505,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT05369429","title":"My Wellbeing Guide: a Novel Tool for Managing Stress and Improving Quality of Life","phase":"NA","overall_status":"RECRUITING","enrollment_count":6516,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT05541302","title":"Retrospective TMS Therapy for Adults With MDD","phase":"","overall_status":"COMPLETED","enrollment_count":6456,"lead_sponsor_name":"Neuronetics","has_results":false},{"nct_id":"NCT04162847","title":"Harnessing Mobile Technology to Reduce Mental Health Disorders in College Populations","phase":"NA","overall_status":"COMPLETED","enrollment_count":6205,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT04863300","title":"Collaborative Stepped-Care and Productive Ageing Program for Older People With Depressive Symptoms","phase":"NA","overall_status":"COMPLETED","enrollment_count":5239,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT06512324","title":"Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness Registry","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":5000,"lead_sponsor_name":"Biomedical Discoveries and Neuroscientific Foundations LLC","has_results":false},{"nct_id":"NCT03951376","title":"Universal Preventive Resilience Intervention to Improve and Promote Mental Health for Teenagers","phase":"NA","overall_status":"UNKNOWN","enrollment_count":4460,"lead_sponsor_name":"Biosistemak Institute for Health Systems Research","has_results":false},{"nct_id":"NCT06251037","title":"\"Youth Aware of Mental Health\" in Galicia","phase":"NA","overall_status":"UNKNOWN","enrollment_count":4453,"lead_sponsor_name":"Fundacin Biomedica Galicia Sur","has_results":false},{"nct_id":"NCT03832283","title":"Patient Outcomes Reporting for Timely Assessments of Life With Depression: PORTAL-Depression","phase":"NA","overall_status":"COMPLETED","enrollment_count":4161,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT03165513","title":"Dialogue to Empower Traditional and Faith Healers to Deliver mhGAP-IG Adapted Psychosocial Interventions in Kenya","phase":"NA","overall_status":"COMPLETED","enrollment_count":4081,"lead_sponsor_name":"Africa Institute of Mental and Brain Health (AFRIMEB)","has_results":false},{"nct_id":"NCT07363980","title":"Coronary Computed Tomography Angiography In Rheumatoid Arthritis Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":4000,"lead_sponsor_name":"Ellen Margrethe Hauge","has_results":false},{"nct_id":"NCT03593889","title":"Collaborative Stepped Care and Peer Support Programme for Older People At-Risk of or With Depression","phase":"NA","overall_status":"COMPLETED","enrollment_count":3702,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT00018057","title":"Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT04307875","title":"Hypertension and Diabetes Assessment in the Rohingya Refugee Population and in the Host Communities in Bangladesh","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"University Hospital Freiburg","has_results":false},{"nct_id":"NCT03354351","title":"Comorbid Mental Disease and Heart Disease in Men","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Universite de Moncton","has_results":false},{"nct_id":"NCT06439316","title":"Physical Function and Mental Health in Cancer Survivors","phase":"","overall_status":"COMPLETED","enrollment_count":2932,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT03790085","title":"Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":2700,"lead_sponsor_name":"Tianjin Medical University General Hospital","has_results":false},{"nct_id":"NCT04586192","title":"Digital Mental Health and Wellness Intervention for Adults: A Randomized Control Trial of COMET","phase":"NA","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT05168722","title":"COVID-19, Patients' Evolution and the Influence of the Pandemic on Health Care and Outcomes in Chronic Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":2220,"lead_sponsor_name":"Hospital Galdakao-Usansolo","has_results":false},{"nct_id":"NCT04632082","title":"Telepsychoeducation for the Prevention of Emotional Distress in Professionals and Students From Essential Services in the Context of COVID-19","phase":"NA","overall_status":"UNKNOWN","enrollment_count":2200,"lead_sponsor_name":"Hospital de Clinicas de Porto Alegre","has_results":false},{"nct_id":"NCT06332261","title":"Standardized Assessment in Depression Treatment in Routine Psychiatric Services","phase":"","overall_status":"COMPLETED","enrollment_count":2173,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT04716400","title":"Effectiveness Study of the Intervention \"Stop Sexual Harassment\" in Secondary School","phase":"NA","overall_status":"COMPLETED","enrollment_count":2037,"lead_sponsor_name":"NORCE Norwegian Research Centre AS","has_results":false},{"nct_id":"NCT05800925","title":"Triage Survey for Psychiatry Research Eligibility","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Adams Clinical","has_results":false},{"nct_id":"NCT03794531","title":"Psychosocial, Environmental, and Chronic Disease Trends in Puerto Rico","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Harvard School of Public Health (HSPH)","has_results":false},{"nct_id":"NCT07189689","title":"Mental Health Mission Mood Disorder Cohort Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT01794559","title":"Study to Evaluate the Safety and Efficacy of PEER Interactive Versus Treatment as Usual in Subjects With a Primary Diagnosis of Depression","phase":"NA","overall_status":"SUSPENDED","enrollment_count":1922,"lead_sponsor_name":"MYnd Analytics","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}